---
ticker: "CANC"
name: "Tema Oncology ETF"
url: "https://etf.net/etf/CANC"
grade: "D"
score: 30
graded_at: "2026-10-12"
category: "Biotech & Genomics"
category_rank: "17 of 17"
methodology: "https://etf.net/methodology"
---

# CANC: Tema Oncology ETF

Grade **D**, Score 30 of 100. Rank 17 of 17 in Biotech & Genomics.

Graded Oct 12, 2026.

## Grade pillars

| Pillar | Score | Category rank |
| --- | --- | --- |
| Cost | 0 | 17 of 17 |
| Mission | Not scored | — |
| Risk | 55 | 9 of 17 |
| Tradability | 36 | 11 of 17 |
| Holdings | 71 | 5 of 17 |
| Durability | 41 | 12 of 17 |

## Top holdings

The fund holds 58 positions. These are the largest 30, by weight.

| # | Ticker | Name | Weight |
| --- | --- | --- | --- |
| 1 | RVMD | Revolution Medicines Inc | 5.54% |
| 2 | MRK | Merck & Co Inc | 5.28% |
| 3 | LLY | Eli Lilly & Co | 4.67% |
| 4 | COGT | Cogent Biosciences Inc | 4.55% |
| 5 | NOVN.SW | Novartis AG | 3.82% |
| 6 | GMAB | Genmab A/S | 3.74% |
| 7 | ABBV | AbbVie Inc | 3.68% |
| 8 | ONC | Beone Medicines Ltd | 3.46% |
| 9 | IOVA | Iovance Biotherapeutics Inc | 3.38% |
| 10 | EXEL | Exelixis Inc | 3.28% |
| 11 | HALO | Halozyme Therapeutics Inc | 3.23% |
| 12 | BMY | Bristol-Myers Squibb Co | 3.04% |
| 13 | BBIO | Bridgebio Pharma Inc | 2.72% |
| 14 | RHHBY | Roche Holding AG | 2.68% |
| 15 | IDYA | Ideaya Biosciences Inc | 2.60% |
| 16 | JNJ | Johnson & Johnson | 2.54% |
| 17 | IMNM | Immunome Inc | 2.49% |
| 18 | CGON | Cg Oncology Inc | 2.48% |
| 19 | ELVN | Enliven Therapeutics Inc | 2.34% |
| 20 | AZN.L | Astrazeneca PLC | 2.09% |
| 21 | ERAS | Erasca Inc | 2.07% |
| 22 | RLAY | Relay Therapeutics Inc | 2.00% |
| 23 | ZLAB | Zai Lab Ltd | 1.87% |
| 24 | SMMT | Summit Therapeutics Inc | 1.80% |
| 25 | LEGN | Legend Biotech Corp | 1.78% |
| 26 | CELC | Celcuity Inc | 1.43% |
| 27 | AMGN | Amgen Inc | 1.36% |
| 28 | ZYME | Zymeworks Inc | 1.27% |
| 29 | NTRA | Natera Inc | 1.22% |
| 30 | KURA | Kura Oncology Inc | 1.11% |

Source: etf.net, https://etf.net/etf/CANC. Please cite the page URL.